Charles River Laboratories International (CRL) Capital Expenditures (2009 - 2025)

Charles River Laboratories International's Capital Expenditures history runs 17 years deep, the most recent figure standing at $89.0 million for Q4 2025.

• In Q4 2025, Capital Expenditures rose 17.63% year-over-year to $89.0 million; the TTM figure through Dec 2025 stood at $219.2 million (down 5.93% YoY), while the FY2025 annual figure was $219.2 million, down 5.93% from the prior year.
• Capital Expenditures for Q4 2025 stood at $89.0 million, up from $35.6 million in the prior quarter.
• The five-year high for Capital Expenditures was $106.9 million in Q2 2023, with the low at $28.0 million in Q1 2021.
• The 5-year median for Capital Expenditures is $69.9 million (2022), against an average of $66.2 million.
• The sharpest annual moves came in 2021 and 2024: Capital Expenditures surged 286.04% in 2021, then sank 41.4% in 2024.
• Charles River Laboratories International's Capital Expenditures stood at $98.8 million in 2021, then dropped by 9.87% to $89.0 million in 2022, then fell by 12.02% to $78.3 million in 2023, then slipped by 3.46% to $75.6 million in 2024, then climbed by 17.63% to $89.0 million in 2025.
• Business Quant data shows CRL's Capital Expenditures at $89.0 million in Q4 2025, $35.6 million in Q3 2025, and $35.3 million in Q2 2025.